Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone
Journal of Bone and Joint Surgery · 2025
DOI: 10.2106/jbjs.24.00184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, 2025. Verfasst von Julian Wier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California. Hauptthemen laut MEDLINE: Dexamethasone, Postoperative Complications, Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Background
Complete blood cell count-based ratios (CBRs), including the neutrophil-lymphocyte ratio (NLR) and monocyte-lymphocyte ratio (MLR), are inflammatory markers associated with postoperative morbidity. Given the link between the surgical stress response and complications after total joint arthroplasty (TJA), this study aimed to evaluate whether higher preoperative CBR values predict greater postoperative benefits associated with dexamethasone utilization.
Methods
The Premier Healthcare Database was queried for adult patients who underwent primary, elective total hip or knee arthroplasty (THA or TKA). Multivariable logistic regression models using dexamethasone exposure and CBRs as independent variables assessed primary end points of 90-day postoperative complications and length of stay (LOS) of ≥3 days. The probability difference between the dexamethasone and non-dexamethasone groups for each primary end point was determined across all values of each CBR. Probability differences were compared across CBR quartiles.
Results
A total of 32,849 primary, elective TJAs (12,788 THAs [38.93%], 20,061 TKAs [61.07%]) performed between 2016 and 2021 were identified, and 22,282 (67.83%) of the patients received perioperative dexamethasone. Among patients with an NLR value of >1.00, those receiving dexamethasone had a lower probability of postoperative complications (all p < 0.05). Dexamethasone was associated with lower odds of an LOS of ≥3 days among patients in the highest NLR quartile (≥4.67) compared with the lowest quartile (NLR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California.
- Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, Washington.
ORCID-Profile: Ian A Jones, Ryan Palmer, Cory K Mayfield, Nicholas J Kassebaum, Jay R Lieberman, Nathanael D Heckmann
Zitieren
APA
Wier, J., Jones, I. A., Palmer, R., Mayfield, C. K., Kassebaum, N. J., Lieberman, J. R., & Heckmann, N. D. (2025). Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.24.00184
Vancouver
Wier J, Jones IA, Palmer R, Mayfield CK, Kassebaum NJ, Lieberman JR, et al. Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone. Journal of Bone and Joint Surgery. 2025. doi:10.2106/jbjs.24.00184
BibTeX
@article{Wier2025,
author = {Wier, Julian and Jones, Ian A and Palmer, Ryan and Mayfield, Cory K and Kassebaum, Nicholas J and Lieberman, Jay R and Heckmann, Nathanael D},
title = {Complete Blood Cell Count-Based Ratios Identify Total Joint Arthroplasty Patients Likely to Benefit from Perioperative Dexamethasone},
journal = {Journal of Bone and Joint Surgery},
year = {2025},
doi = {10.2106/jbjs.24.00184}
}
EUVIMED